Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
OVIDREL vs ANDEMBRY
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
OVIDREL (choriogonadotropin alfa) acts as a luteinizing hormone (LH) agonist, binding to the LH/choriogonadotropin receptor on ovarian theca and granulosa cells, triggering ovulation and luteinization by inducing resumption of oocyte meiosis and follicle rupture.
Binds to androgens, progesterone, and estradiol, inhibiting their effects on hormone-responsive tissues; also binds to microtubules and inhibits tubulin polymerization.
Induction of final follicular maturation and early luteinization in infertile women undergoing controlled ovarian hyperstimulation (COH) for assisted reproductive technologies (ART),Induction of ovulation in anovulatory or oligo-ovulatory women who have been pretreated with follicle-stimulating hormone (FSH)
Castration-resistant prostate cancer (chemotherapy-naïve or docetaxel-treated),Metastatic castration-resistant prostate cancer
250 mcg subcutaneously once daily for 7 days following recombinant FSH stimulation. Alternatively, a single 250 mcg subcutaneous dose is used to trigger final follicular maturation 24-48 hours after last gonadotropin dose.
ANDEMBRY (capivasertib) 400 mg orally twice daily, taken with or without food, in combination with fulvestrant. Continue until disease progression or unacceptable toxicity.
The terminal elimination half-life is approximately 30 hours (range 20-48 hours) in healthy adults. This supports a single-dose regimen for final follicular maturation in assisted reproductive technology.
Terminal elimination half-life is 12-15 hours in healthy adults; may be prolonged up to 20-25 hours in patients with moderate to severe hepatic impairment.
Primarily metabolized in the kidney and other tissues via proteolytic degradation into amino acids and peptides; not significantly metabolized by cytochrome P450 enzymes.
Hepatic via CYP3A4; active metabolites include abiraterone sulfate, abiraterone N-oxide, and abiraterone glucuronide.
Primarily renal, with approximately 10% of the administered dose excreted unchanged in urine within 24 hours. The remainder undergoes metabolic degradation in the kidneys and liver.
Primarily renal excretion of unchanged drug (approximately 70-80%) and as metabolites (10-15%); biliary/fecal elimination accounts for less than 10%.
Highly bound to plasma proteins, predominantly albumin, with approximately 80-85% bound.
Approximately 95% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein.
Approximately 6 L (0.1 L/kg in a 60 kg adult), indicating limited distribution primarily to the extracellular space.
Volume of distribution is 0.6-0.8 L/kg, indicating distribution into total body water and some tissue binding.
Subcutaneous injection: approximately 80% absolute bioavailability. Not administered orally.
Oral bioavailability is 85-90%; intravenous administration yields 100% bioavailability.
No specific dose adjustment guidelines; use caution in renal impairment. GFR <30 m L/min: consider alternatives due to potential accumulation.
No dose adjustment required for mild-to-moderate renal impairment (Cr Cl ≥30 m L/min). Not studied in severe renal impairment (Cr Cl <30 m L/min) or end-stage renal disease; avoid use.
No specific dose adjustment guidelines; use caution in severe hepatic impairment (Child-Pugh C).
Mild hepatic impairment (Child-Pugh A): no dose adjustment. Moderate hepatic impairment (Child-Pugh B): reduce dose to 320 mg orally twice daily. Severe hepatic impairment (Child-Pugh C): not recommended.
Not indicated for pediatric use; no established pediatric dosing.
Safety and efficacy not established in pediatric patients (<18 years); no recommended dose.
Not indicated for geriatric use; no standard dosing established.
No specific dose adjustment required based on age. Monitor renal function and for increased risk of adverse events (e.g., diarrhea, hyperglycemia) in elderly patients.
None (no FDA black box warning for OVIDREL).
None.
Ovarian hyperstimulation syndrome (OHSS): can be severe with pulmonary and vascular complications; monitor closely and discontinue if OHSS develops.,Ovarian torsion: risk is increased in patients with enlarged ovaries; evaluate for abdominal pain.,Respiratory distress syndrome: associated with severe OHSS.,Multiple pregnancy: increased risk; counsel patients on potential outcomes.,Congenital malformations: incidence may increase following gonadotropin therapy; no causal link established.,Thromboembolic events: increased risk, especially in patients with obesity, thrombophilia, or prior history.
Hepatotoxicity, mineralocorticoid excess, cardiovascular events, adrenal insufficiency, and bone marrow suppression.
Hypersensitivity to choriogonadotropin alfa or any component of the formulation,Pituitary or hypothalamic tumors,Ovarian enlargement or cyst due to reasons other than polycystic ovary syndrome,Gynecological hemorrhage of unknown etiology,Ovarian, uterine, or breast carcinoma,Active thromboembolic disorders or prior history of the same,Primary ovarian failure,Uncontrolled thyroid or adrenal dysfunction
Hypersensitivity to abiraterone acetate or any component, severe hepatic impairment (Child-Pugh C), and women who are or may become pregnant.
No known significant food interactions. Grapefruit may affect metabolism of certain hormones; avoid excessive grapefruit intake.
ANDEMBRY can be taken with or without food. However, grapefruit and grapefruit juice may increase trofinetide levels; avoid concurrent consumption. No other significant food interactions reported.
OVIDREL (choriogonadotropin alfa) is not indicated for use during pregnancy. Based on its mechanism as a luteinizing hormone analog, inadvertent exposure during early pregnancy may theoretically support corpus luteum function, but no increased risk of congenital anomalies has been reported in postmarketing surveillance. First trimester: No known teratogenic risk, but limited data. Second trimester: Not applicable as not used. Third trimester: Not applicable.
Category X. First trimester: Major congenital malformations (neural tube defects, craniofacial abnormalities). Second/third trimester: Spontaneous abortion, fetal death, growth restriction. Contraindicated in pregnancy.
No data available on the excretion of choriogonadotropin alfa into human breast milk. The M/P ratio is unknown. Given its large molecular weight (~30-40 k Da), transfer into milk is likely low, but caution is recommended. Use during lactation only if clearly needed.
Excreted in human milk; M/P ratio unknown. Potential for serious adverse effects in nursing infant. Contraindicated during breastfeeding.
OVIDREL is not indicated during pregnancy. No dose adjustment studies in pregnancy exist. If inadvertently administered during early pregnancy, the same dose (single SC injection of 250 mcg or 5000-10000 IU) is retained, but no therapeutic need. Pharmacokinetic changes due to pregnancy (e.g., increased volume of distribution) are not clinically relevant as the drug is a single-dose trigger.
Do not use in pregnancy. No dose recommendations available; contraindicated.
OVIDREL (choriogonadotropin alfa) is a recombinant human chorionic gonadotropin (h CG) used to trigger final follicular maturation and ovulation in assisted reproductive technology (ART). Administer subcutaneously exactly 36 hours before oocyte retrieval; timing is critical. Monitor for ovarian hyperstimulation syndrome (OHSS) risk, especially in patients with polycystic ovary syndrome (PCOS). Do not use in patients with primary ovarian failure or uncontrolled thyroid/adrenal dysfunction.
ANDEMBRY (trofinetide) is indicated for the treatment of Rett syndrome. Administer orally twice daily with or without food. Monitor for diarrhea and vomiting, which are common adverse effects; consider dose reduction or temporary discontinuation if severe. Assess liver enzymes and bilirubin before and during treatment due to potential hepatotoxicity. Avoid use in patients with severe hepatic impairment. Do not crush or chew capsules; for patients unable to swallow, sprinkle contents onto soft food and administer immediately.
Inject OVIDREL exactly as prescribed, at the same time each day if multiple doses are needed.,Common side effects include injection site reactions, headache, and nausea.,Contact your doctor immediately if you experience severe pelvic pain, nausea, vomiting, or weight gain (signs of OHSS).,OVIDREL may cause false positive pregnancy tests; consult your doctor if you get a positive result.
Take ANDEMBRY exactly as prescribed, twice daily with or without food.,If you miss a dose, skip it and take the next dose at the regular time; do not double the dose.,Common side effects include diarrhea and vomiting; inform your doctor if these become severe or persistent.,Avoid alcohol while taking this medication as it may increase the risk of liver injury.,Report any signs of liver problems such as yellowing of skin or eyes, dark urine, or abdominal pain.,Do not crush or chew the capsules; if you have trouble swallowing, open the capsule and mix the contents with a small amount of soft food (e.g., applesauce) and take immediately.,Keep this medication out of reach of children and store at room temperature away from moisture.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about OVIDREL vs ANDEMBRY, answered by our medical review team.
OVIDREL is a Gonadotropin that works by OVIDREL (choriogonadotropin alfa) acts as a luteinizing hormone (LH) agonist, binding to the LH/choriogonadotropin receptor on ovarian theca and granulosa cells, triggering ovulation and luteinization by inducing resumption of oocyte meiosis and follicle rupture.. ANDEMBRY is a Gonadotropin that works by Binds to androgens, progesterone, and estradiol, inhibiting their effects on hormone-responsive tissues; also binds to microtubules and inhibits tubulin polymerization.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between OVIDREL and ANDEMBRY depend on the specific clinical indication. These are both Gonadotropin agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of OVIDREL is: 250 mcg subcutaneously once daily for 7 days following recombinant FSH stimulation. Alternatively, a single 250 mcg subcutaneous dose is used to trigger final follicular maturation 24-48 hours after last gonadotropin dose.. The standard adult dose of ANDEMBRY is: ANDEMBRY (capivasertib) 400 mg orally twice daily, taken with or without food, in combination with fulvestrant. Continue until disease progression or unacceptable toxicity.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between OVIDREL and ANDEMBRY in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. OVIDREL is classified as Category C. OVIDREL (choriogonadotropin alfa) is not indicated for use during pregnancy. Based on its mechanism as a luteinizing hormone analog, inadvertent exposure during early pregnancy may. ANDEMBRY is classified as Category C. Category X. First trimester: Major congenital malformations (neural tube defects, craniofacial abnormalities). Second/third trimester: Spontaneous abortion, fetal death, growth res. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.